{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:45:24Z","timestamp":1790358324645,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007421","name":"Li Ka Shing Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008149","name":"Royal College of Pathologists of Australasia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008149","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1169460"],"award-info":[{"award-number":["APP1169460"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1177305"],"award-info":[{"award-number":["1177305"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Mesothelin (MSLN) is a cancer\u2010associated antigen that is overexpressed in malignancies such as mesothelioma, pancreatic and ovarian cancer. It is also a target for novel personalised therapies, including antibodies, antibody\u2013drug conjugates and chimeric antigen receptor T cells. Immunohistochemistry may predict those who would best respond to anti\u2010mesothelin therapies and guide decisions in therapeutic strategy. This study aimed to assess the intensity and distribution of MSLN immunostaining in mesothelioma, and to determine the prognostic value of MSLN expression by histochemical\u2010score (H\u2010score).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      The MN1 anti\u2010MSLN antibody was used to stain a formalin\u2010fixed paraffin\u2010embedded tissue microarray of histologically confirmed mesothelioma from 75 consecutive patients who had undergone pleurectomy with or without decortication. MSLN positivity, the staining intensity, distribution of staining and H\u2010score were evaluated. The correlation of H\u2010score with prognosis was investigated. Sixty\u2010six per cent of epithelioid tumours were MSLN\u2010positive (with expression in &gt;\u20095% tumour cells). Of MSLN\u2010expressing epithelioid tumours, 70.4% had moderate (2+) or strong (3+) intensity MSLN immunostaining, although only 37% of samples had staining in \u2265\u200950% of tumour cells. In multivariate analysis, MSLN H\u2010score as a continuous variable and an H\u2010score\u2009\u2265\u200933 were independent predictors of improved survival (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MSLN expression was more heterogenous in epithelioid mesothelioma than reported previously. Therefore, it would be appropriate to perform an immunohistochemical assessment of MSLN expression to stratify and assess patient suitability for mesothelin\u2010targeted personalised therapies, such as chimeric antigen receptor T cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/his.14916","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T19:58:58Z","timestamp":1681243138000},"page":"202-210","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma"],"prefix":"10.1111","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9033-4554","authenticated-orcid":false,"given":"Gerard J","family":"Chu","sequence":"first","affiliation":[{"name":"Gene and Stem Cell Therapy Program Centenary Institute University of Sydney  Sydney NSW Australia"},{"name":"Department of Clinical Immunology and Allergy Royal Prince Alfred Hospital  Camperdown NSW Australia"},{"name":"Faculty of Medicine and Health University of Sydney  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Linton","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health University of Sydney  Sydney NSW Australia"},{"name":"Department of Medical Oncology Concord Hospital  Concord NSW Australia"},{"name":"Asbestos Diseases Research Institute  Concord NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health University of Sydney  Sydney NSW Australia"},{"name":"Asbestos Diseases Research Institute  Concord NSW Australia"},{"name":"Department of Medical Oncology Chris O'Brien Lifehouse  Camperdown NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[{"name":"Asbestos Diseases Research Institute  Concord NSW Australia"},{"name":"Department of Anatomical Pathology Flinders University and SA Pathology  Adelaide SA Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Adelstein","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Allergy Royal Prince Alfred Hospital  Camperdown NSW Australia"},{"name":"Faculty of Medicine and Health University of Sydney  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dannel","family":"Yeo","sequence":"additional","affiliation":[{"name":"Gene and Stem Cell Therapy Program Centenary Institute University of Sydney  Sydney NSW Australia"},{"name":"Faculty of Medicine and Health University of Sydney  Sydney NSW Australia"},{"name":"Cell and Molecular Therapies, Royal Prince Alfred Hospital  Camperdown NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E J","family":"Rasko","sequence":"additional","affiliation":[{"name":"Gene and Stem Cell Therapy Program Centenary Institute University of Sydney  Sydney NSW Australia"},{"name":"Faculty of Medicine and Health University of Sydney  Sydney NSW Australia"},{"name":"Cell and Molecular Therapies, Royal Prince Alfred Hospital  Camperdown NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-4229","authenticated-orcid":false,"given":"Wendy A","family":"Cooper","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health University of Sydney  Sydney NSW Australia"},{"name":"Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology Royal Prince Alfred Hospital  Camperdown NSW Australia"},{"name":"School of Medicine Western Sydney University  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M806776200"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01464-5"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200907-1020OC"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.8.2902-2906.2000"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2610"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400062111"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI88845"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0688"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0314-2"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-106"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2614"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15814"},{"key":"e_1_2_8_14_1","first-page":"9","article-title":"Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors","volume":"9","author":"Weidemann S","year":"2021","journal-title":"Biomedicine"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0124-RA"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00061-4"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28875"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0804"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0693"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-CT105"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407"},{"key":"e_1_2_8_22_1","unstructured":"Phase I study of autologous T cells bearing fully\u2010humanized chimeric antigen receptor targeting mesothelin in mesothelin expressing cancers.2021https:\/\/www.med.upenn.edu\/cellicon2021\/assets\/user\u2010content\/documents\/tanyi.pdf."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.03.029"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200308000-00001"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2003.11.013"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02279.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200302000-00002"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100260"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2007.02080.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20845"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.05.024"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.731"},{"key":"e_1_2_8_33_1","volume-title":"World Health Organisation classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart","author":"Travis WBE","year":"2004"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0578"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17436"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-5-47"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-013-1146-6"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0804"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.121"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1971"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.10.050"}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.14916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:50:18Z","timestamp":1692319818000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/his.14916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/his.14916"],"URL":"https:\/\/doi.org\/10.1111\/his.14916","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"assertion":[{"value":"2022-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}